Advertisement
Singapore markets open in 7 hours 33 minutes

  • Straits Times Index

    3,307.90
    -6.15 (-0.19%)
     

  • S&P 500

    5,319.01
    -2.40 (-0.05%)
     

  • Dow

    39,817.84
    -55.15 (-0.14%)
     

  • Nasdaq

    16,833.71
    +1.09 (+0.01%)
     

  • Bitcoin USD

    70,282.95
    +564.87 (+0.81%)
     

  • CMC Crypto 200

    1,520.93
    -5.49 (-0.36%)
     

  • FTSE 100

    8,370.33
    -46.12 (-0.55%)
     

  • Gold

    2,395.20
    -30.70 (-1.27%)
     

  • Crude Oil

    78.07
    -0.59 (-0.75%)
     

  • 10-Yr Bond

    4.4180
    +0.0040 (+0.09%)
     

  • Nikkei

    38,617.10
    -329.83 (-0.85%)
     

  • Hang Seng

    19,195.60
    -25.02 (-0.13%)
     

  • FTSE Bursa Malaysia

    1,622.09
    -5.41 (-0.33%)
     

  • Jakarta Composite Index

    7,222.38
    +36.34 (+0.51%)
     

  • PSE Index

    6,607.22
    -26.44 (-0.40%)
     

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024

PR Newswire
·2-min read

LEXINGTON, Mass., April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET.

(PRNewsfoto/Curis, Inc.)
(PRNewsfoto/Curis, Inc.)

To access the live conference call, please dial (800)-836-8184 from the United States or (646)-357-8785 from other locations, shortly before 8:30 a.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), both of which have received Orphan Drug Designation from the U.S. Food and Drug Administration. Emavusertib is also being evaluated as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-release-first-quarter-2024-financial-results-and-hold-conference-call-on-may-7-2024-302131015.html

SOURCE Curis, Inc.